2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Hodgkin Disease
3
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Recurrence
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell
1
Lymphoma
1
Interventions
Cyclophosphamide
45
Prednisone
31
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
29
Vincristine
28
Doxorubicin
27
Etoposide
22
romidepsin
20
Gemcitabine
18
Lenalidomide
16
10-propargyl-10-deazaaminopterin
16
fludarabine phosphate
15
Whole-Body Irradiation
15
Peripheral Blood Stem Cell Transplantation
14
Brentuximab Vedotin
14
Azacitidine
13
Mycophenolic Acid
12
Dexamethasone
10
Cyclosporine
10
Bortezomib
10
Alemtuzumab
10
Rituximab
8
fludarabine
7
belinostat
7
Methotrexate
6
Cytarabine
6
Busulfan
6
Bendamustine Hydrochloride
6
pembrolizumab
5
denileukin diftitox
5
Nivolumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, T-Cell, Peripheral
×
AFM13
×
Clear all
NCT05883449
2025-08-20
LuminICE-203
Affimed GmbH
Phase 2
Terminated
25 enrolled
21 charts
NCT04101331
2024-11-05
REDIRECT
Affimed GmbH
Phase 2
Completed
108 enrolled
24 charts